Abstract:T-Antigen (Gal-beta1,3-GalNAc-alpha-O-Ser/Thr) is an important precursor of mucin-type O-glycans. T-Antigen is found to be closely associated with cancer progression and metastasis and has been used to develop carbohydrate-based anticancer vaccines. Enzymatic synthesis of T-antigen disaccharides have relied on the use of beta-1,3-galactosyltransferases recently cloned and characterized from several eukaryotic organisms. However, its application is limited by the difficulty of obtaining homogeneous enzymes and the strict substrate specificity of enzymes. Recently, a number of bacteria have been found to express carbohydrate structures that mimic host glycans. The corresponding glycosyltransferases have been exploited in the facile synthesis of a number of clinically important glycoconjugate mimics. In this study, we biochemically characterized a bacterial beta-1,3-galactosyltransferase (WbiP) from Escherichia coli O127, which expresses a T-antigen mimic in the lipopolysaccharide (LPS) structure. Substrate study showed that WbiP could readily glycosylate a series of N-acetylgalactosamine (GalNAc) analogues with alpha-substitutions at the reducing end, including glycosylated Ser and Thr (GalNAc-alpha-O-Ser/Thr), which illustrates the use of WbiP for the facile synthesis of T-antigens. Alignment of a group of putative bacterial beta-1,3-galactosyltransferases revealed the presence of two conserved DXD motifs, possibly suggesting a different functional role of each motif. Site-directed mutagenesis, enzyme kinetics as well as UDP-bead binding assays were carried out to investigate the role of each DXD motif in WbiP. The results suggest that 88DSD90 is critical in the binding of sugar donor UDP-Gal, whereas 174DYD176 may participate in the binding of the sugar acceptor. This study expands the scope of using bacterial glycosyltransferases as tools for in vitro synthesis of glycoconjugate mimics with clinical significance.

Altering the Modular Architecture of Galectins Affects its Binding with Synthetic α-Dystroglycan O-Mannosylated Core M1 Glycoconjugates In situ

Characterization of a Bacterial Beta-1,3-galactosyltransferase with Application in the Synthesis of Tumor-Associated T-antigen Mimics.

Tailoring GalNAcα1-3Galβ-specific Lectins from a Multi-Specific Fungal Galectin: Dramatic Change of Carbohydrate Specificity by a Single Amino-Acid Substitution

Glycosylation of α-dystroglycan: O-mannosylation influences the subsequent addition of GalNAc by UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases

Synthesis and Biological Activities of Amino Acids Functionalized Α-Galcer Analogues.

Mutational Tuning of Galectin-3 Specificity and Biological Function

Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient

First demonstration of differential inhibition of lectin binding by synthetic tri- and tetravalent glycoclusters from cross-coupling of rigidified 2-propynyl lactoside

Comprehensive Modular Synthesis of Ganglioside Glycans and Evaluation of their Binding Affinities to Siglec‐7 and Siglec‐9

Exploring the Galectin Network by Light and Fluorescence Microscopy

Dissecting the Structure–Activity Relationship of Galectin–Ligand Interactions

Different roles of the heterodimer architecture of galectin-4 in selective recognition of oligosaccharides and lipopolysaccharides having ABH antigens

Novel Fluorescent Glycan Microarray Strategy Reveals Ligands for Galectins

Chemoenzymatic Modular Assembly of O-GalNAc Glycans for Functional Glycomics

An acetylation site in lectin domain modulates the biological activity of polypeptide GalNAc-transferase-2

Linker remodels human Galectin-8 structure and regulates its hemagglutination and pro-apoptotic activity

An unusual dual sugar-binding lectin domain controls the substrate specificity of a mucin-type O-glycosyltransferase

Characterization of Galectin Fusion Proteins with Glycoprotein Affinity Columns and Binding Assays

Therapeutic Benefit of Galectin-1: Beyond Membrane Repair, a Multifaceted Approach to LGMD2B

Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models

Rational Design of Cell Active C2-modified DGJ Analogues for the Inhibition of Human Α-Galactosidase A (GALA).